Yaojing Chen, Mingxi Dang & Zhanjun Zhang
Featured Review: “Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies
Yuxing Xia, Stefan Prokop & Benoit I. Giasson
Alzheimer's Disease: Challenges for the next decade
Molecular Neurodegeneration presents a new thematic series, collating reviews which present and evaluate the challenges for the next decade of research into Alzheimer's disease.
Edited by Guojun Bu, Alison Goate and Todd Golde, reviews will continue to publish throughout 2021. The collection can be read here.
News from Alzforum
23 June 2021
Contact the Managing Editorial Team
Hongmei Li - Hongmei.Li@MolecularNeurodegeneration.org
Lucy Job - Lucy.Job@MolecularNeurodegeneration.org
The leading open access journal in the field of neurosciences, Molecular Neurodegeneration encompasses all aspects of neurodegeneration research at the molecular and cellular levels.
Molecular Neurodegeneration is the official journal of the BrightFocus Foundation.
Annual Journal Metrics
58 days to first decision for reviewed manuscripts only
31 days to first decision for all manuscripts
153 days from submission to acceptance
28 days from acceptance to publication
723 Altmetric mentions